Needham Downgrades G1 Therapeutics to Hold
Portfolio Pulse from Benzinga Newsdesk
Needham analyst Gil Blum has downgraded G1 Therapeutics (NASDAQ:GTHX) from Buy to Hold.
August 07, 2024 | 8:09 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Needham analyst Gil Blum has downgraded G1 Therapeutics from Buy to Hold, indicating a less optimistic outlook on the stock.
The downgrade from Buy to Hold by a reputable analyst suggests a less favorable view on the stock's short-term performance, likely leading to a negative impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100